This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
New study analyzes early antibody binding to decellularized homografts
Semi-quantitative analysis by a newly developed Dot-Blot showed early binding of preformed antibody binding in 20 consecutive patients, which were followed after pulmonary and aortic valve replacement with cell-free homografts....
European Journal for Cardiothoracic Surgery publishes ESPOIR 5-year data
A 5-year analysis of ESPOIR Trial patients was performed to provide an insight into the midterm performance of decellularized pulmonary homografts (DPH). ESPOIR Trial and Registry patients were matched with cryopreserved...
5-year ESPOIR Trial results and ESPOIR Registry Data to be presented at the DGTHG/DGPK 2022
The 5-year results of the prospective European multi-centre ESPOIR trial will be presented as an on-demand presentation within the 2022 DGTHG/DGPK meeting in Hamburg. The talk will also focus on the available longterm data from...
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.